Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02176018 · ClinicalTrials.gov registry record · Phase 2
Nuedexta for the Prevention and Modification of Disease Progression in Episodic Migraine
A Phase 2 study, sponsored by Cady, Roger, M.D..
- Completed
- Registry status
- Phase 2
- Development phase
- 76
- Enrollment target
NCT02176018: Completed Phase 2 study, sponsored by Cady, Roger, M.D..
NCT02176018 is a Phase 2 study that has completed, run by Cady, Roger, M.D.. The registered enrollment target is 76 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (43% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02176018, a Phase 2 study, has completed, sponsored by Cady, Roger, M.D..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 76 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and effectiveness of daily dextromethorphan/quinidine (Nuedexta) in reducing the frequency and progression of episodic migraine.
Primary Outcome
The average number of headache days at treatment period months 1, 2, and 3 (28 day periods for each month) for the Nuedexta arm and the Placebo arm. Headache days were defined as any patient reported head pain during the prior 24 hour period.
Interventions
- DRUG Placebo
- DRUG Dextromethorphan and quinidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2014-08 |
| Est. Completion | 2017-03 |
| Phase | Phase 2 |
What the finished NCT02176018 record still lists
NCT02176018 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 76 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (43% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02176018 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02176018 about?
NCT02176018 is a clinical study titled "Nuedexta for the Prevention and Modification of Disease Progression in Episodic Migraine". The purpose of this study is to evaluate the efficacy and effectiveness of daily dextromethorphan/quinidine (Nuedexta) in reducing the frequency and progression of episodic migraine.
What is the current status of trial NCT02176018?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2014-08. Estimated completion is 2017-03.
What interventions are being tested in trial NCT02176018?
The interventions under investigation include: Placebo (DRUG), Dextromethorphan and quinidine (DRUG).
Who is sponsoring clinical trial NCT02176018?
This trial is sponsored by Cady, Roger, M.D., which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02176018's enrollment target sits among peer trials
76 893rd of 2000 higher than 1,101 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02615184 · 76 participants · Phase 2
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
- NCT02821741 · 76 participants · NA
Effects of External Ear Stimulation on Pain Perception and Mood
- NCT03019757 · 76 participants
Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease
- NCT03353584 · 76 participants · NA
Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia